News | February 09, 2026
Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Subscribe To Our Newsletter & Stay Updated
